References
- GBD 2019 Stroke Collaborators. Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurol. 2021; 20:795–820.
- Katan M, Luft A. Global burden of stroke. Semin Neurol. 2018; 38:208–11.
- Truelsen T, Krarup LH, Iversen HK, Mensah GA, Feigin VL, Sposato LA, Naghavi M. Causes of death data in the global burden of disease estimates for ischemic and hemorrhagic stroke. Neuroepidemiology. 2015; 45:152–60.
- Cramer SC. Treatments to promote neural repair after stroke. J Stroke. 2018; 20:57–70.
- Pittenger MF, Discher DE, Péault BM, Phinney DG, Hare JM, Caplan AI. Mesenchymal stem cell perspective: cell biology to clinical progress. NPJ Regen Med. 2019; 4:22. doi: 10.1038/s41536-019-0083-6
- Wechsler LR, Bates D, Stroemer P, Andrews-Zwilling YS, Aizman I. Cell therapy for chronic stroke. Stroke. 2018; 49:1066–74.
- Rebelatto CK, Aguiar AM, Moretão MP, Senegaglia AC, Hansen P, Barchiki F, et al. Dissimilar differentiation of mesenchymal stem cells from bone marrow, umbilical cord blood, and adipose tissue. Exp Biol Med (Maywood). 2008; 233:901–13.
- Stanko P, Kaiserova K, Altanerova V, Altaner C. Comparison of human mesenchymal stem cells derived from dental pulp, bone marrow, adipose tissue, and umbilical cord tissue by gene expression. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2014; 158:373–7.
- Shen LH, Li Y, Chen J, Zacharek A, Gao Q, Kapke A, et al. Therapeutic benefit of bone marrow stromal cells administered 1 month after stroke. J Cereb Blood Flow Metab. 2007; 27:6–13.
- Yasuhara T, Matsukawa N, Hara K, Maki M, Ali MM, Yu SJ, et al. Notch-induced rat and human bone marrow stromal cell grafts reduce ischemic cell loss and ameliorate behavioral deficits in chronic stroke animals. Stem Cells Dev. 2009; 18:1501–14.
- Kenmuir CL, Wechsler LR. Update on cell therapy for stroke. Stroke Vasc Neurol. 2017; 2:59–64.
- Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. doi: 10.1136/bmj.n71
- Wells G, Shea B, O’Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. 2012. Available from:
https://www.ohri.ca/programs/clinical_epidemiology/oxford . - Chiu TL, Baskaran R, Tsai ST, Huang CY, Chuang MH, Syu WS, et al. Intracerebral transplantation of autologous adipose-derived stem cells for chronic ischemic stroke: a phase I study. J Tissue Eng Regen Med. 2022; 16:3–13.
- Levy ML, Crawford JR, Dib N, Verkh L, Tankovich N, Cramer SC. Phase I/II study of safety and preliminary efficacy of intravenous allogeneic mesenchymal stem cells in chronic stroke. Stroke. 2019; 50:2835–41.
- Steinberg GK, Kondziolka D, Wechsler LR, Lunsford LD, Kim AS, Johnson JN, et al. Two-year safety and clinical outcomes in chronic ischemic stroke patients after implantation of modified bone marrow–derived mesenchymal stem cells (SB623): a phase 1/2a study. J Neurosurg. 2018; 131:1462–72.
- Bhasin A, Kumaran SS, Bhatia R, Mohanty S, Srivastava MVP. Safety and feasibility of autologous mesenchymal stem cell transplantation in chronic stroke in Indian patients. A four-year follow up. J Stem Cells Regen Med. 2017; 13:14–9.
- Bhasin A, Srivastava P, Kumaran S, Pawan K, Mewar S. Bone marrow derived mononuclear stem cells in chronic stroke: functional imaging & spectroscopic analysis. J Neurol Sci. 2019; 405:26–7.
- Simpson E, Dazzi F. Bone marrow transplantation 1957–2019. Front Immunol. 2019; 10:1246. doi: 10.3389/fimmu.2019.01246
- Dameshek W. Bone marrow transplantation: a present-day challenge. Blood. 1957; 12:321–3.
- Kabat M, Bobkov I, Kumar S, Grumet M. Trends in mesenchymal stem cell clinical trials 2004–2018: is efficacy optimal in a narrow dose range? Stem Cells Transl Med. 2020; 9:17–27.
- Nagpal A, Choy FC, Howell S, Hillier S, Chan F, Hamilton-Bruce MA, Koblar SA. Safety and effectiveness of stem cell therapies in early-phase clinical trials in stroke: a systematic review and meta-analysis. Stem Cell Res Ther. 2017; 8:191. doi: 10.1186/s13287-017-0643-x
- Kondziolka D, Wechsler L, Goldstein S, Meltzer C, Thulborn KR, Gebel J, et al. Transplantation of cultured human neuronal cells for patients with stroke. Neurology. 2000; 55:565–9.
- Kondziolka D, Steinberg GK, Wechsler L, Meltzer CC, Elder E, Gebel J, et al. Neurotransplantation for patients with subcortical motor stroke: a phase 2 randomized trial. J Neurosurg. 2005; 103:38–45.
- Chen L, Zhang G, Khan AA, Guo X, Gu Y. Clinical efficacy and meta-analysis of stem cell therapies for patients with brain ischemia. Stem Cells Int. 2016; 2016:6129579. doi: 10.1155/2016/6129579
- Bang OY, Kim EH, Cha JM, Moon GJ. Adult stem cell therapy for stroke: challenges and progress. J Stroke. 2016; 18:256–66.
- Symon L, Crockard HA, Dorsch NW, Branston NM, Juhasz J. Local cerebral blood flow and vascular reactivity in a chronic stable stroke in baboons. Stroke. 1975; 6:482–92.
- Janowski M, Wagner DC, Boltze J. Stem cell-based tissue replacement after stroke: factual necessity or notorious fiction? Stroke. 2015; 46:2354–63.
- Sharma RR, Pollock K, Hubel A, McKenna D. Mesenchymal stem or stromal cells: a review of clinical applications and manufacturing practices. Transfusion. 2014; 54:1418–37.
- Shi L, Wang L, Xu R, Zhang C, Xie Y, Liu K, et al. Mesenchymal stem cell therapy for severe COVID-19. Signal Transduct Target Ther. 2021; 6:339. doi: 10.1038/s41392-021-00754-6
- Vahidy FS, Rahbar MH, Zhu H, Rowan PJ, Bambhroliya AB, Savitz SI. Systematic review and meta-analysis of bone marrow-derived mononuclear cells in animal models of ischemic stroke. Stroke. 2016; 47:1632–9.
- Jingli Y, Jing W, Saeed Y. Ischemic brain stroke and mesenchymal stem cells: an overview of molecular mechanisms and therapeutic potential. Stem Cells Int. 2022; 2022:5930244. doi: 10.1155/2022/5930244
- Zhou L, Zhu H, Bai X, Huang J, Chen Y, Wen J, et al. Potential mechanisms and therapeutic targets of mesenchymal stem cell transplantation for ischemic stroke. Stem Cell Res Ther. 2022; 13:195. doi: 10.1186/s13287-022-02876-2
- Singh M, Pandey PK, Bhasin A, Padma MV, Mohanty S. Application of stem cells in stroke: a multifactorial approach. Front Neurosci. 2020; 14:473. doi: 10.3389/fnins.2020.00473
- Zacharek A, Chen J, Cui X, Li A, Li Y, Roberts C, et al. Angiopoietin1/Tie2 and VEGF/Flk1 induced by MSC treatment amplifies angiogenesis and vascular stabilization after stroke. J Cereb Blood Flow Metab. 2007; 27:1684–91.
- Song M, Mohamad O, Gu X, Wei L, Yu SP. Restoration of intracortical and thalamocortical circuits after transplantation of bone marrow mesenchymal stem cells into the ischemic brain of mice. Cell Transplant. 2013; 22:2001–15.
- Ding R, Lin C, Wei S, Zhang N, Tang L, Lin Y, et al. Therapeutic benefits of mesenchymal stromal cells in a rat model of hemoglobin-induced hypertensive intracerebral hemorrhage. Mol Cells. 2017; 40:133–42.
- Wang C, Fei Y, Xu C, Zhao Y, Pan Y. Bone marrow mesenchymal stem cells ameliorate neurological deficits and blood-brain barrier dysfunction after intracerebral hemorrhage in spontaneously hypertensive rats. Int J Clin Exp Pathol. 2015; 8:4715–24.
- Zhang Y, Dong N, Hong H, Qi J, Zhang S, Wang J. Mesenchymal stem cells: therapeutic mechanisms for stroke. Int J Mol Sci. 2022; 23:2550. doi: 10.3390/ijms23052550
- Shiota Y, Nagai A, Sheikh AM, Mitaki S, Mishima S, Yano S, et al. Transplantation of a bone marrow mesenchymal stem cell line increases neuronal progenitor cell migration in a cerebral ischemia animal model. Sci Rep. 2018; 8:14951. doi: 10.1038/s41598-018-33030-9